Affiliation:
1. Department of Biology, Faculty of Medicine, Masaryk University, Kamenice 5, Building A6, 62500 Brno, Czech Republic
2. Department of Clinical Immunology and Allergology, Faculty of Medicine, Masaryk University, 62500 Brno, Czech Republic
Abstract
Defects in cell death signaling pathways are one of the hallmarks of cancer and can lead to resistance to conventional therapy. Natural products are promising compounds that can overcome this resistance. In the present study we studied the effect of six quaternary benzophenanthridine alkaloids (QBAs), sanguinarine, chelerythrine, sanguirubine, chelirubine, sanguilutine, and chelilutine, on Jurkat leukemia cells, WT, and cell death deficient lines derived from them, CASP3/7/6-/- and FADD-/-, and on solid tumor, human malignant melanoma, A375 cells. We demonstrated the ability of QBAs to overcome the resistance of these deficient cells and identified a novel mechanism for their action. Sanguinarine and sanguirubine completely and chelerythrine, sanguilutine, and chelilutine partially overcame the resistance of CASP3/7/6-/- and FADD-/- cells. By detection of cPARP, a marker of apoptosis, and pMLKL, a marker of necroptosis, we proved the ability of QBAs to induce both these cell deaths (bimodal cell death) with apoptosis preceding necroptosis. We identified the new mechanism of the cell death induction by QBAs, the downregulation of the apoptosis inhibitors cIAP1 and cIAP2, i.e., an effect similar to that of Smac mimetics.
Funder
Ministry of Education, Youth, and Sports
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference38 articles.
1. Small-Molecule SMAC Mimetics as New Cancer Therapeutics;Bai;Pharmacol. Ther.,2014
2. Inhibitor of Apoptosis Proteins as Therapeutic Targets in Multiple Myeloma;Ramakrishnan;Leukemia,2014
3. Initial Testing (Stage 1) of LCL161, a SMAC Mimetic, by the Pediatric Preclinical Testing Program;Houghton;Pediatr. Blood Cancer,2012
4. West, A.C., Martin, B.P., Andrews, D.A., Hogg, S.J., Banerjee, A., Grigoriadis, G., Johnstone, R.W., and Shortt, J. (2016). The SMAC Mimetic, LCL-161, Reduces Survival in Aggressive MYC-Driven Lymphoma While Promoting Susceptibility to Endotoxic Shock. Oncogenesis, 5.
5. Necroptosis: Mechanisms and Relevance to Disease;Galluzzi;Annu. Rev. Pathol.,2017